Repligen’s (RGEN) Buy Rating Reaffirmed at HC Wainwright
Repligen (NASDAQ:RGEN – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $180.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 13.21% from the company’s […]
Repligen (NASDAQ:RGEN – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $180.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 13.21% from the company’s […]
